Post-Transcriptional Modification by Alternative Splicing and Pathogenic Splicing Variants in Cardiovascular Development and Congenital Heart Defects
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24021555 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Zubin Mehta und 1 weiteren Autor:innen. Beteiligte Einrichtung: Neonatal/Congenital Heart Laboratory, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA. Hauptthemen laut MEDLINE: Alternative Splicing, Heart Defects, Congenital. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, 2021 UCLA Broad Stem Cell Research Center (BSCRC) T32 Training grant, NIH/NHLBI.
Abstract (Originalsprache)
Advancements in genomics, bioinformatics, and genome editing have uncovered new dimensions in gene regulation. Post-transcriptional modifications by the alternative splicing of mRNA transcripts are critical regulatory mechanisms of mammalian gene expression. In the heart, there is an expanding interest in elucidating the role of alternative splicing in transcriptome regulation. Substantial efforts were directed toward investigating this process in heart development and failure. However, few studies shed light on alternative splicing products and their dysregulation in congenital heart defects (CHDs). While elegant reports showed the crucial roles of RNA binding proteins (RBPs) in orchestrating splicing transitions during heart development and failure, the impact of RBPs dysregulation or genetic variation on CHDs has not been fully addressed. Herein, we review the current understanding of alternative splicing and RBPs’ roles in heart development and CHDs. Wediscuss the impact of perinatal splicing transition and its dysregulation in CHDs. We further summarize the discoveries made of causal splicing variants in key transcription factors that are implicated in CHDs. An improved understanding of the roles of alternative splicing in heart development and CHDs may potentially inform novel preventive and therapeutic advancements for newborn infants with CHDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neonatal/Congenital Heart Laboratory, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
- Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
- Children's Discovery and Innovation Institute, Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
- Eli and Edythe Broad Stem Cell Research Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
ORCID-Profile: Marlin Touma
Förderung
- NHLBI NIH HHS
- 2021 UCLA Broad Stem Cell Research Center (BSCRC) T32 Training grant
- NIH/NHLBI
- Department of Defense-Congressionally Directed Medical Research Programs
- 2022 UCLA Academic Senate Faculty Research Fund
Zitieren
APA
Mehta, Z., & Touma, M. (2023). Post-Transcriptional Modification by Alternative Splicing and Pathogenic Splicing Variants in Cardiovascular Development and Congenital Heart Defects. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021555
Vancouver
Mehta Z, Touma M. Post-Transcriptional Modification by Alternative Splicing and Pathogenic Splicing Variants in Cardiovascular Development and Congenital Heart Defects. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24021555
BibTeX
@article{Mehta2023,
author = {Mehta, Zubin and Touma, Marlin},
title = {Post-Transcriptional Modification by Alternative Splicing and Pathogenic Splicing Variants in Cardiovascular Development and Congenital Heart Defects},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24021555}
}
EUVIMED